The Manufacturers Life Insurance Company Takes $1.42 Million Position in Tyra Biosciences, Inc. $TYRA

Key Points

• The Manufacturers Life Insurance Company acquired 44,327 Tyra Biosciences shares worth approximately $1.42 million, while other major institutions—including BlackRock and Commodore Capital—also increased or initiated positions. Institutional investors collectively own 84.14% of the company.
• Tyra shares were trading at $24.86, down 1.1%, and remain below their 50-day and 200-day moving averages. The company reported a quarterly loss of $0.69 per share, missing analyst expectations of a $0.65 loss.
• Analysts maintain a generally positive outlook, with 12 Buy ratings, one Hold, and one Sell; the consensus rating is Moderate Buy with a $48.22 price target, well above the current share price.

The Manufacturers Life Insurance Company acquired a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 44,327 shares of the company's stock, valued at approximately $1,416,000. The Manufacturers Life Insurance Company owned approximately 0.07% of Tyra Biosciences as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Tyra Biosciences during the 2nd quarter worth about $96,841,000. Commodore Capital LP raised its position in shares of Tyra Biosciences by 226.3% during the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company's stock worth $29,667,000 after acquiring an additional 2,150,000 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Tyra Biosciences by 32.5% during the first quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company's stock worth $148,867,000 after purchasing an additional 955,147 shares during the last quarter. Farallon Capital Management LLC lifted its stake in Tyra Biosciences by 80.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company's stock worth $54,337,000 after purchasing an additional 923,000 shares during the last quarter. Finally, Jennison Associates LLC acquired a new position in Tyra Biosciences in the first quarter valued at approximately $24,222,000. Hedge funds and other institutional investors own 84.14% of the company's stock.

Tyra Biosciences Trading Down 1.1%

NASDAQ TYRA opened at $24.86 on Friday. The business's 50 day moving average is $29.09 and its two-hundred day moving average is $32.05. Tyra Biosciences, Inc. has a 12-month low of $11.70 and a 12-month high of $40.65. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -10.36 and a beta of 0.73.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.04). Equities analysts forecast that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on TYRA shares. Bank of America boosted their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a "buy" rating in a research report on Wednesday, June 10th. HC Wainwright restated a "buy" rating and issued a $45.00 price objective on shares of Tyra Biosciences in a research note on Thursday, May 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Tyra Biosciences in a report on Friday, July 17th. JonesTrading started coverage on Tyra Biosciences in a research report on Wednesday, June 17th. They issued a "buy" rating and a $56.00 target price for the company. Finally, Wolfe Research assumed coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They issued a "peer perform" rating on the stock. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Tyra Biosciences has an average rating of "Moderate Buy" and a consensus target price of $48.22.

About Tyra Biosciences

Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source